Journal of Clinical Pediatrics >
Clinical analysis of severe cytokine release syndrome caused by CAR-T cell therapy in children's intensive care unit
Received date: 2021-04-08
Online published: 2022-11-10
Objective To analyze the clinical features of severe cytokine release syndrome (sCRS) in children with relapsed B lineage acute lymphoblastic leukemia (B-ALL) treated by CAR-T cell therapy, and to summarize their treatment methods. Methods The clinical data of 14 cases of CAR-T cell therapy relapsed B-ALL children admitted to the intensive care unit from January 2019 to June 2020 were collected, and retrospectively analyzed. Results After CAR-T cell infusion, nine cases developed sCRS, eleven children developed hemodynamic instability, five cases required mechanical ventilation, ten cases had neurological symptoms, and seven cases had liver damage. All 14 patients were treated with tocilizumab, some of them were given glucocorticoids, and five patients were treated with continuous blood purification. Three patients died, and eleven patients recovered within two weeks. Conclusion CRS is a common toxic reaction after CAR-T cell infusion, which can cause multiple organ dysfunction. The severity of CRS was positively correlated with the levels of cytokines IL-6 and IFN-γ. Tocilizumab and corticosteroids are the main treatments, and the blood purification can also be used as a special treatment for CRS.
Qiujiao ZHU , Tao PAN , Zhenjiang BAI , Xin DING , Ying LI . Clinical analysis of severe cytokine release syndrome caused by CAR-T cell therapy in children's intensive care unit[J]. Journal of Clinical Pediatrics, 2022 , 40(11) : 848 -853 . DOI: 10.12372/jcp.2022.21e0516
| [1] | Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia[J]. Haematologica, 2020, 105(11): 2524-2539. |
| [2] | Nguyen K, Devidas M, Cheng SC, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children’s Oncology Group study[J]. Leukemia, 2008, 22(12): 2142-2150. |
| [3] | Pehlivan KC, Duncan BB, Lee DW. CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease[J]. Curr Hematol Malig Rep, 2018, 13(5): 396-406. |
| [4] | Rosenbaum L. Tragedy, perseverance, and chance - the story of CAR-T therapy[J]. N Engl J Med, 2017, 377(14): 1313-1315. |
| [5] | Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells[J]. Biol Blood Marrow Transplant, 2019, 25(4): 625-638. |
| [6] | Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome[J]. Blood, 2014, 124(2): 188-195. |
| [7] | Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CART-cell therapry for B-cell lymphomas: clinical trial results of available products[J]. Ther Adv Hematol, 2019, 10: 2040620719841581. |
| [8] | Li L, Liu J, Xu M, et al. Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients[J]. Cell Death Dis, 2020, 11(3): 207. |
| [9] | Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia[J]. N Engl J Med, 2014, 371(16): 1507-1517. |
| [10] | Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia[J]. N Engl J Med, 2018, 378(5): 439-448. |
| [11] | Santomasso B, Bachier C, Westin J, et al. The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden[J]. Am Soc Clin Oncol Educ Book, 2019, 39: 433-444. |
| [12] | Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia[J]. Hematology Am Soc Hematol Educ Program, 2016, 2016(1): 567-572. |
| [13] | Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome[J]. Blood, 2014, 124(2): 188-195. |
| [14] | Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy[J]. Biol Blood Marrow Transplant, 2019, 25(4): e123-e127. |
| [15] | Hirayama AV, Turtle CJ. Toxicities of CD19 CAR-T cell immunotherapy[J]. Am J Hematol, 2019, 94(S1): S42-S49. |
| [16] | Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management[J]. Blood, 2016, 127(26): 3321-3330. |
| [17] | Oved JH, Barrett DM, Teachey DT. Cellular therapy: immune-related complications[J]. Immunol Rev, 2019, 290(1): 114-126. |
| [18] | Grigor EJM, Fergusson D, Kekre N, et al. Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis[J]. Transfus Med Rev, 2019, 33(2): 98-110. |
| [19] | Gust J, Finney OC, Li D, et al. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy[J]. Ann Neurol, 2019, 86(1): 42-54. |
| [20] | Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL[J]. Bone Marrow Transplant, 2021, 56(3): 552-566. |
| [21] | Neelapu SS. Managing the toxicities of CAR T-cell therapy[J]. Hematol Oncol, 2019, 37(Suppl 1): 48-52. |
| [22] | Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells[J]. Cancer Discov, 2017, 7(12): 1404-1419. |
| [23] | Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial[J]. Lancet, 2015, 385(9967): 517-528. |
| [24] | Scheller J, Chalaris A, Schmidt-Arras D, et al. The pro- and anti-inflammatory properties of the cytokine interleukin-6[J]. Biochim Biophys Acta, 2011, 1813(5): 878-888. |
| [25] | Shank BR, Do B, Sevin A, et al. Chimeric antigen receptor T cells in hematologic malignancies[J]. Pharmacotherapy, 2017, 37(3): 334-345. |
| [26] | Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome[J]. Expert Rev Clin Immunol, 2019, 15(8): 813-822. |
| [27] | Brudno JN, Kochenderfer JN. Recent advance in CAR T-cell toxicity: mechanisms, manifestations and management[J]. Blood Rev, 2019, 34: 45-55. |
| [28] | Fischer JW, Bhattarai N. CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities[J]. Front Immunol, 2021, 12: 693016. |
| [29] | Liu Y, Chen X, Wang D, et al. Hemofiltration successfully eliminates severe cytokine release syndrome following CD19 CAR-T-cell therapy[J]. J Immunother, 2018, 41(9): 406-410. |
| [30] | Xiao X, He X, Li Q, et al. Plasma exchange can be an alternative therapeutic modality for severe cytokine release syndrome after chimeric antigen receptor-T cell infusion: a case report[J]. Clin Cancer Res, 2019, 25(1): 29-34. |
/
| 〈 |
|
〉 |
